Business
Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting
WESTLAKE VILLAGE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"WESTLAKE VILLAGE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will showcase data on its investigational program studying topical roflumilast cream (ARQ-151) in patients with chronic plaque psoriasis at the 2020 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO, on March 20-24, 2020.\n “We are delighted to participate in the scientific exchange at this year’s AAD meeting,” said Howard Welgus, MD, Chief Medical Officer at Arcutis. “Patients and dermatologists need new and better topical treatment options that provide improved efficacy, safety and tolerability for patients with plaque psoriasis. We look forward to sharing data that demonstrate how topical roflumilast cream could, if approved, provide a once daily treatment option that effectively addresses the current challenges of treating plaque psoriasis with topical therapies.\" Title: ARQ-151, Roflumilast Cream, Significantly Improves Chronic Plaque Psoriasis in Phase 2b StudySession: S027 - Late-breaking Research: Clinical TrialsPresenter: Dr. Linda Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at the Henry Ford Hospital in Detroit, MichiganDate: Saturday, March 21, 9:00 – 9:10 a.m. MTLocation: Bellco Theatre 2 In addition, results from the Phase 1/2a study of topical roflumilast cream in chronic plaque psoriasis have been accepted for an e-poster presentation. Title: ARQ-151, Roflumilast Cream, Improved Psoriasis in Phase 2a StudyAbstract/poster number: 15309Date: ePosters will be presented Friday, March 20 - Sunday, March 22, 9 a.m. - 5 p.m. MT About Topical Roflumilast Cream (ARQ-151)Topical roflumilast cream (ARQ-151) is a topical cream formulation containing roflumilast, a PDE4 inhibitor, that Arcutis is developing to treat plaque psoriasis, including intertriginous psoriasis, and atopic dermatitis. PDE4 is an intracellular enzyme that regulates pro-inflammatory and anti-inflammatory cytokine production and cell proliferation. Roflumilast was approved by the FDA for systemic treatment to reduce risk of exacerbation of chronic obstructive pulmonary disease (COPD) in 2011, and has show...